Actively Recruiting

Phase 2
Age: 12Years +
All Genders
NCT06364176

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Led by University of Kansas Medical Center · Updated on 2025-05-02

42

Participants Needed

1

Research Sites

173 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF) on modulator therapy. The main question it aims to answer is if treatment with losartan improves response of the CF transmembrane conductance regulator (CFTR) channel to modulator therapy. Participants will be asked take losartan or placebo for twelve weeks and will have changes in sweat chloride levels measured as a marker of CFTR function.

CONDITIONS

Official Title

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Established diagnosis of cystic fibrosis
  • Age 12 years and older
  • Stable use of elexacaftor/tezacaftor/ivacaftor for 90 days prior to enrollment
  • Sweat chloride concentration 50 mmol/L or greater while on elexacaftor/tezacaftor/ivacaftor
Not Eligible

You will not qualify if you...

  • Prior lung transplant
  • BMI less than 18
  • CF pulmonary exacerbation requiring hospitalization or intravenous antibiotics in the preceding 30 days
  • Systemic corticosteroid or regular non-steroidal anti-inflammatory use in the preceding 30 days
  • Chronic use of angiotensin receptor blockers or angiotensin converting enzyme inhibitors
  • Concomitant use of medications known to interact with losartan, including aliskiren
  • Chronic renal insufficiency (creatinine clearance less than 45 ml/min)
  • Pregnancy or lactation
  • Inability or unwillingness to comply with approved contraceptive method during the study period (females of childbearing age)
  • In the opinion of the investigator any severe or acute or chronic condition or laboratory abnormality that may increase the risk associated with trial participation or make the participant inappropriate for enrollment
  • Participation in another interventional trial that, in the opinion of the investigator, has the potential to affect the primary outcome

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Kansas Medical Center

Kansas City, Kansas, United States, 66160

Actively Recruiting

Loading map...

Research Team

H

Heidi Hellwig

CONTACT

C

Carolina Aguiar

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis. | DecenTrialz